Corcept Therapeutics (NASDAQ:CORT) posted its earnings results on Thursday. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.03, Fidelity Earnings reports. The firm had revenue of $81.51 million during the quarter, compared to analysts’ expectations of $77.86 million. Corcept Therapeutics had a net margin of 29.16% and a return on equity of 27.97%. The company’s revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.22 earnings per share.
NASDAQ CORT traded up $0.41 during trading on Friday, reaching $15.01. The company’s stock had a trading volume of 1,863,000 shares, compared to its average volume of 928,963. The stock has a market capitalization of $1.63 billion, a PE ratio of 25.02 and a beta of 1.35. The business has a 50-day moving average price of $14.25 and a 200-day moving average price of $12.18. Corcept Therapeutics has a 1-year low of $9.14 and a 1-year high of $19.48.
A number of analysts have issued reports on the stock. BidaskClub upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, October 29th. TheStreet upgraded shares of Corcept Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, August 16th. Zacks Investment Research upgraded shares of Corcept Therapeutics from a “sell” rating to a “hold” rating and set a $12.00 target price for the company in a research note on Wednesday, July 31st. ValuEngine cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, HC Wainwright assumed coverage on shares of Corcept Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $15.00.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Read More: What are the benefits of investing in REITs?
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.